Antipsychotic drugs: A new risk factor for osteoporosis in young women with schizophrenia?

Journal of Clinical Psychopharmacology

Volumn 25, Issue 1, 2005, Pages 26-31

  O'Keane, Veronica ^a   Meaney, Anna Maria ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; SEX HORMONE;

ADULT; AMENORRHEA; ARTICLE; BLOOD SAMPLING; BONE DENSITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; MENSTRUATION DISORDER; OLIGOMENORRHEA; OSTEOPENIA; OSTEOPOROSIS; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RISK FACTOR; SCHIZOPHRENIA;

ADULT; ALCOHOL DRINKING; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; BONE DENSITY; BONE DISEASES, METABOLIC; DENSITOMETRY, X-RAY; FEMALE; GONADAL STEROID HORMONES; HUMANS; HYPERPROLACTINEMIA; HYPOGONADISM; MENSTRUATION DISTURBANCES; OSTEOPOROSIS; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; RISK FACTORS; SCHIZOPHRENIA; SMOKING;

EID: 12344332245     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000150223.31007.e0     Document Type: Article

References (29)

1. Heiskanen T, Niskanen L, Lyytikainen R, et al. J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64:575-579.
2. Biller BM, Heronzog DB, Rosenthal DI, et al. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J Clin Endocrinol Metab. 1989;68:548-554.
3. Lindholm J, Steiniche T, Rasmussen E, et al. Bone disorder in men with chronic alcoholism: a reversible disease? J Clin Endocrinol Metab. 1991;73:118-124.
4. Robbins J, Hirsch C, Whitmer C, et al. The association of bone mineral density and depression in an older population. J Am Geriatr Soc. 2001; 49:827-828.
5. Schweiger U, Deuschle M, Korner A, et al. Low lumbar bone density in patients with depression. Am J Psychiatry. 1994;151:1691-1693.
6. Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med. 1995;57: 485-491.
7. Abraham G, Freidman RH, Verghese C. Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients. Biol Psychiatry. 1996;40:430-431.
8. Schlecte J, El-Khoury B, Martin R. Bone density in amenorrhoeic women with and without hyperprolactinaemia. J Clin Endocrinol Metab. 1983;56:1120-1123.
9. Schlechte J, Walkner L, Kathol M. A longitudinal Analysis of premenopausal bone loss in healthy women and women with hyperprolactinaemia. J Clin Endocrinol Metab. 1992;75:698-702.
10. Halbreich U, Kinon BJ, Gilmore JA, et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;28:53-67.
11. Wieck A, Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. BMJ. 2002;324:250-252.
12. Smith S, Wheeler M, Murray R, et al. The effects of anti-psychotic induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002;22:109-114.
13. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinaemia in schizophrenic patients treated with conventional antipsychotic medication or risperidone. Psychoneuroendocrinology. 2003;28:55-68.
14. Overall JE, Graham DR. The Brief Psychiatric Rating Scale. Reports. 1962;10:799-812.
15. Andreason N. Scale for Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1983.
16. Theodorou DJ, Theodorou SJ. Dual-energy X-ray absorptiometry in clinical practice: application and interpretation of scans beyond the numbers. Clin Imaging. 2002;26:43-49.
17. Kapur S, Zipursky R, Jones C. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520.
18. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother. 2002;10:1381-1391.
19. Meaney AM, Smith S, Howes O, et al. The effect of long-term prolactin-raising antipsychotic medication on bone mineral density inpatients with schizophrenia. Br J Psychiatry. 2004;184:503-508.
20. Adler RA, Evani R, Mansouri A, et al. Relative effects of prolactin excess and estrogen deficiency on bone in rats. Metabolism. 1998;47:425-428.
21. Tay CC, Glasier AF, Illingworth PJ. Abnormal twenty-four hour pattern of pulsatile luteinizing hormone secretion and the response to naloxone in women with hyperprolactinaemic amenorrhoea. Clin Endocrinol (Oxf). 1993;39:599-606.
22. Stiegler C, Leb G, Kleinert R, et al. Plasma levels of parathyroid hormone-related peptide are elevated in hyperprolactinaemia and correlated to bone density status. J Bone Miner Res. 1995;10:751-759.
23. Adami S, Zamberlan N, Castello R, et al. Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol (Oxf). 1998;48:169-173.
24. Yoshimura N, Kasamatsu T, Sakata K, et al. The relationship between endogenous oestrogen, sex hormone binding globulin and bone loss in female residents of a rural Japanese community: the Taiji study. J Bone Miner Metab. 2002;20:303-310.
25. Abraham G, Paing WW, Kaminski J, et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry. 2003;160:1618-1620.
26. Bilici M, Cakirbay H, Guler M, et al. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci. 2002;112:817-822.
27. Becker D, Liver O, Mester R, et al. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry. 2003;64:761-767.
28. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. WHO Technical Report Series 843, Geneva, Switzerland: WHO; 1994.
29. Smith SM, Murray R, O'Keane V. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry. 2002;181:49-55.